Potent Dual mTOR Inhibitor: AZD2014 for Advanced Cancer Research
Explore the groundbreaking potential of AZD2014, a dual mTORC1/mTORC2 inhibitor revolutionizing cancer therapy research.
Get a Quote & SampleProduct Core Value
Dual mTORC1 and mTORC2 Inhibitor
AZD2014 stands out as a novel, potent, and highly selective dual inhibitor of the mammalian target of rapamycin (mTORC1 and mTORC2). This orally administered compound possesses significant potential antineoplastic activity, making it a key subject in advanced cancer research and drug development.
- Discover the antineoplastic activity of AZD2014 as a dual mTORC1 and mTORC2 inhibitor, crucial for developing next-generation cancer treatments.
- Learn how AZD2014 induces apoptosis, autophagy, and cell cycle arrest, leading to substantial proliferation suppression of cancer cells.
- Explore the synergistic effects of AZD2014 when combined with other inhibitors, offering promising therapeutic methods for diseases like diffuse large B-cell lymphoma.
- Understand the role of AZD2014 in enhancing the radiosensitivity of glioblastoma stem-like cells, a critical factor in improving radiation therapy outcomes.
Key Product Advantages
Unmatched Selectivity and Potency
AZD2014 offers exceptional selectivity and potency as a dual mTORC1/mTORC2 inhibitor, with an IC50 of just 2.8 nM, ensuring targeted action against cancer pathways.
Broad Antineoplastic Potential
The compound's ability to induce apoptosis, autophagy, and cell cycle arrest positions it as a versatile agent in fighting various cancers, including breast and liver cancers.
Enhanced Therapeutic Strategies
AZD2014's synergistic effects with other agents and its capacity to improve radiation therapy outcomes present novel avenues for combination treatments in oncology.
Key Applications
Oncology Drug Development
AZD2014 serves as a vital compound in the preclinical development of new antineoplastic drugs targeting the mTOR pathway.
Cancer Research Studies
Researchers utilize AZD2014 to investigate cellular mechanisms related to cancer progression, apoptosis, and drug resistance.
Targeted Therapy Advancement
The dual inhibition of mTORC1 and mTORC2 makes AZD2014 instrumental in advancing targeted therapy strategies for complex cancers.
Radiosensitization Research
Studies explore AZD2014's role in enhancing the effectiveness of radiation therapy in challenging cancers like glioblastoma.